JHL Biotech, a biopharmaceutical company, has opened a biopharmaceutical manufacturing facility with single-use bioprocessing technology in Wuhan, China.

The facility uses the KUBio manufacturing solution delivered by GE Healthcare to manufacture biosimilars and monoclonal antibodies (mAbs) for late–stage clinical trials and commercial supply. The facility will also provide process development and manufacturing services for JHL's global customer base.

JHL and GE Healthcare partnered to complete the construction of the facility in 18 months using GE's KUBio manufacturing solution. KUBio is a prefabricated cGMP-compliant facility and process solution designed for scalable manufacturing.

JHL's new facility in Wuhan has the same standardized GE FlexFactory technology as its existing site in Taiwan, which allows it to scale up to a capacity of 2,000 liters.

The JHL Center of Excellence in Taiwan does biosimilar pre-clinical and early-clinical phase R&D work. JHL's facility in Wuhan, China will do commercial-scale manufacturing of biologic therapies.

Source: JHL Biotech